Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: Yiska Weisblum Clear advanced filters

  • A complex range of mutations within the SARS-CoV-2 spike protein is needed to escape polyclonal plasma neutralizing antibodies, and plasma from individuals who were first infected then vaccinated display the greatest resilience to escape mutations.

    • Fabian Schmidt
    • Yiska Weisblum
    • Paul D. Bieniasz
    Research
    Nature
    Volume: 600, P: 512-516

  • The Moderna (mRNA-1273) and Pfizer–BioNTech (BNT162b2) vaccines elicit anti-RBD antibodies similar to those elicited through natural infection with SARS-CoV-2, but their potent neutralizing activity was reduced or abolished by new viral variants of concern.

    • Zijun Wang
    • Fabian Schmidt
    • Michel C. Nussenzweig
    Research
    Nature
    Volume: 592, P: 616-622

  • Although rare, antibodies against the receptor-binding domain of SARS-CoV-2 that showed potent antiviral activity were obtained from all tested convalescent individuals, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.

    • Davide F. Robbiani
    • Christian Gaebler
    • Michel C. Nussenzweig
    Research
    Nature
    Volume: 584, P: 437-442

  • In a cohort of 87 individuals with COVID-19, the memory B cell response at 6.2 months after the onset of disease evolves in a manner that is consistent with the persistence of SARS-CoV-2 antigen.

    • Christian Gaebler
    • Zijun Wang
    • Michel C. Nussenzweig
    Research
    Nature
    Volume: 591, P: 639-644